HER2DX ERBB2 mRNA expression in advanced HER2- positive breast cancer treated with T-DM1
In advanced HER2-positive (HER2+) breast cancer (BC), the new antibody-drug conjugate trastuzumab deruxtecan (T-DXd) is more effective compared to trastuzumab emtansine (T-DM1). However, T-DXd can have significant toxicities, and the right treatment sequence is unknown. Biomarkers to guide the use o...
| Authors: | ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; |
|---|---|
| Format: | Article |
| Status: | Accepted version |
| Publication date: | 2022 |
| Country: | España |
| Institution: | Universidad de Barcelona |
| Repository: | Dipòsit Digital de la UB |
| OAI Identifier: | oai:diposit.ub.edu:2445/194390 |
| Online Access: | https://hdl.handle.net/2445/194390 |
| Access Level: | Open access |
| Keyword: | Tumors cerebrals Metàstasi Càncer de mama Expressió gènica Cèl·lules T Brain tumors Metastasis Breast cancer Gene expression T cells |
| _version_ | 1878739615057182720 |
|---|---|
| author | Brasó-Maristany, Fara |
| author2 | Griguolo, Gaia Chic Ruché, Núria Pascual, Tomás Paré Brunet, Laia Maues, Julia Galván, Patricia Dieci, Maria Vittoria Miglietta, Federica Giarratano, Tommaso Martínez-Sáez, Olga Marín Aguilera, Mercedes Schettini, Francesco Conte, Benedetta Angelats, Laura Vidal Losada, Maria Jesús Adamo, Barbara Muñoz, Montse Sanfeliu Torres, Esther González Farré, Blanca Vivancos, Ana Villagrasa, Patricia Parker, Joel S. Perou, Charles M. Conte, Pierfranco Prat Aparicio, Aleix Guarneri, Valentina |
| author2_role | author author author author author author author author author author author author author author author author author author author author author author author author author author |
| author_browse | Adamo, Barbara Angelats, Laura Brasó-Maristany, Fara Chic Ruché, Núria Conte, Benedetta Conte, Pierfranco Dieci, Maria Vittoria Galván, Patricia Giarratano, Tommaso González Farré, Blanca Griguolo, Gaia Guarneri, Valentina Martínez-Sáez, Olga Marín Aguilera, Mercedes Maues, Julia Miglietta, Federica Muñoz, Montse Parker, Joel S. Paré Brunet, Laia Pascual, Tomás Perou, Charles M. Prat Aparicio, Aleix Sanfeliu Torres, Esther Schettini, Francesco Vidal Losada, Maria Jesús Villagrasa, Patricia Vivancos, Ana |
| author_facet | Brasó-Maristany, Fara Griguolo, Gaia Chic Ruché, Núria Pascual, Tomás Paré Brunet, Laia Maues, Julia Galván, Patricia Dieci, Maria Vittoria Miglietta, Federica Giarratano, Tommaso Martínez-Sáez, Olga Marín Aguilera, Mercedes Schettini, Francesco Conte, Benedetta Angelats, Laura Vidal Losada, Maria Jesús Adamo, Barbara Muñoz, Montse Sanfeliu Torres, Esther González Farré, Blanca Vivancos, Ana Villagrasa, Patricia Parker, Joel S. Perou, Charles M. Conte, Pierfranco Prat Aparicio, Aleix Guarneri, Valentina |
| author_role | author |
| collection | Dipòsit Digital de la UB |
| description | In advanced HER2-positive (HER2+) breast cancer (BC), the new antibody-drug conjugate trastuzumab deruxtecan (T-DXd) is more effective compared to trastuzumab emtansine (T-DM1). However, T-DXd can have significant toxicities, and the right treatment sequence is unknown. Biomarkers to guide the use of anti-HER2 therapies beyond HER2 status are needed. Here, we evaluated if pre-established levels of ERBB2 mRNA expression according to the HER2DX standardized assay are associated with response and survival following T-DM1. In ERBB2 low, medium, and high groups, the overall response rate was 0%, 29% and 56%, respectively (P<.001). ERBB2 mRNA was significantly associated with better progression-free survival (p = 0.002) and overall survival (OS; P = 0.02). These findings were independent of HER2 IHC levels, hormone receptor, age, brain metastasis and line of therapy. The HER2DX risk-score (P=.04) and the immunoglobulin (IGG) signature (P=.04) were significantly associated with OS since diagnosis. HER2DX provides prognostic and predictive information following T-DM1 in advanced HER2+ BC. |
| eu_rights_str_mv | openAccess |
| format | article |
| id | ES_c4d40af3ef0002daa8fb7c19644b81fb |
| institution | Universidad de Barcelona |
| instname_str | Universidad de Barcelona |
| network_acronym_str | ES |
| network_name_str | España |
| oai_identifier_str | oai:diposit.ub.edu:2445/194390 |
| publishDate | 2022 |
| publishDateSort | 2022 |
| publisher | Oxford University Press |
| publisherStr | Oxford University Press |
| reponame_str | Dipòsit Digital de la UB |
| spelling | HER2DX ERBB2 mRNA expression in advanced HER2- positive breast cancer treated with T-DM1 Brasó-Maristany, Fara Griguolo, Gaia Chic Ruché, Núria Pascual, Tomás Paré Brunet, Laia Maues, Julia Galván, Patricia Dieci, Maria Vittoria Miglietta, Federica Giarratano, Tommaso Martínez-Sáez, Olga Marín Aguilera, Mercedes Schettini, Francesco Conte, Benedetta Angelats, Laura Vidal Losada, Maria Jesús Adamo, Barbara Muñoz, Montse Sanfeliu Torres, Esther González Farré, Blanca Vivancos, Ana Villagrasa, Patricia Parker, Joel S. Perou, Charles M. Conte, Pierfranco Prat Aparicio, Aleix Guarneri, Valentina Tumors cerebrals Metàstasi Càncer de mama Expressió gènica Cèl·lules T Brain tumors Metastasis Breast cancer Gene expression T cells In advanced HER2-positive (HER2+) breast cancer (BC), the new antibody-drug conjugate trastuzumab deruxtecan (T-DXd) is more effective compared to trastuzumab emtansine (T-DM1). However, T-DXd can have significant toxicities, and the right treatment sequence is unknown. Biomarkers to guide the use of anti-HER2 therapies beyond HER2 status are needed. Here, we evaluated if pre-established levels of ERBB2 mRNA expression according to the HER2DX standardized assay are associated with response and survival following T-DM1. In ERBB2 low, medium, and high groups, the overall response rate was 0%, 29% and 56%, respectively (P<.001). ERBB2 mRNA was significantly associated with better progression-free survival (p = 0.002) and overall survival (OS; P = 0.02). These findings were independent of HER2 IHC levels, hormone receptor, age, brain metastasis and line of therapy. The HER2DX risk-score (P=.04) and the immunoglobulin (IGG) signature (P=.04) were significantly associated with OS since diagnosis. HER2DX provides prognostic and predictive information following T-DM1 in advanced HER2+ BC. Oxford University Press https://hdl.handle.net/2445/194390 |
| spellingShingle | HER2DX ERBB2 mRNA expression in advanced HER2- positive breast cancer treated with T-DM1 Brasó-Maristany, Fara Tumors cerebrals Metàstasi Càncer de mama Expressió gènica Cèl·lules T Brain tumors Metastasis Breast cancer Gene expression T cells |
| status_str | acceptedVersion |
| title | HER2DX ERBB2 mRNA expression in advanced HER2- positive breast cancer treated with T-DM1 |
| title_full | HER2DX ERBB2 mRNA expression in advanced HER2- positive breast cancer treated with T-DM1 |
| title_fullStr | HER2DX ERBB2 mRNA expression in advanced HER2- positive breast cancer treated with T-DM1 |
| title_full_unstemmed | HER2DX ERBB2 mRNA expression in advanced HER2- positive breast cancer treated with T-DM1 |
| title_short | HER2DX ERBB2 mRNA expression in advanced HER2- positive breast cancer treated with T-DM1 |
| title_sort | HER2DX ERBB2 mRNA expression in advanced HER2- positive breast cancer treated with T-DM1 |
| topic | Tumors cerebrals Metàstasi Càncer de mama Expressió gènica Cèl·lules T Brain tumors Metastasis Breast cancer Gene expression T cells |
| topic_facet | Tumors cerebrals Metàstasi Càncer de mama Expressió gènica Cèl·lules T Brain tumors Metastasis Breast cancer Gene expression T cells |
| url | https://hdl.handle.net/2445/194390 |